These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 32202061)
1. A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas? Koufakis T; Dimitriadis G; Kotsa K J Diabetes; 2020 Jul; 12(7):499-502. PubMed ID: 32202061 [No Abstract] [Full Text] [Related]
6. Does mortality risk vary among sulfonylureas? Pantalone KM Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240 [No Abstract] [Full Text] [Related]
7. Actual problems of the hypoglycaemic sulfonylureas. Káldor A Ther Hung; 1977; 25(2):47-50. PubMed ID: 898117 [No Abstract] [Full Text] [Related]
8. Managing the diabetic patient with acute myocardial infarction. Fisken RA Diabet Med; 1998 Nov; 15(11):980. PubMed ID: 9827854 [No Abstract] [Full Text] [Related]
9. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes. Barry HC Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428 [No Abstract] [Full Text] [Related]
10. [Glipizide, a new sulfonylurea in the treatment of diabetes mellitus]. Villaseñor A Prensa Med Mex; 1973; 38(5):211-4. PubMed ID: 4782089 [No Abstract] [Full Text] [Related]
11. [Evaluation of a new sulfonylurea, glipizide, in the treatment of diabetes mellitus]. Ninni M; Castelletta L Minerva Med; 1973 Oct; 64(71):3725-31. PubMed ID: 4588364 [No Abstract] [Full Text] [Related]
12. [Indications and limitations of oral hypoglycemic agents in the treatment of diabetes mellitus]. Guillon J; Charbonnel B Cah Med; 1972 Nov; 13(14):999-1006. PubMed ID: 4646244 [No Abstract] [Full Text] [Related]
13. Sulfonylurea treatment in type 2 diabetes. Bester K; Ton J; Korownyk C Can Fam Physician; 2018 Apr; 64(4):295. PubMed ID: 29650607 [No Abstract] [Full Text] [Related]
14. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Jollis JG; Simpson RJ; Cascio WE; Chowdhury MK; Crouse JR; Smith SC Am Heart J; 1999 Nov; 138(5 Pt 1):S376-80. PubMed ID: 10539800 [No Abstract] [Full Text] [Related]
16. [Therapeutic trial of a new antidiabetic with vascular action: 1702 SE]. Jaillard J; Warembourg H Lille Med; 1972 Oct; 17(9):Suppl 6:1332-6. PubMed ID: 4657429 [No Abstract] [Full Text] [Related]
17. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313 [No Abstract] [Full Text] [Related]
18. The clinical effects of levosimendan are not attenuated by sulfonylureas. Kivikko M; Nieminen MS; Pollesello P; Pohjanjousi P; Colucci WS; Teerlink JR; Mebazaa A Scand Cardiovasc J; 2012 Dec; 46(6):330-8. PubMed ID: 22928945 [TBL] [Abstract][Full Text] [Related]
19. Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke. Floyd JS; Wiggins KL; Christiansen M; Dublin S; Longstreth WT; Smith NL; McKnight B; Heckbert SR; Weiss NS; Psaty BM Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):151-60. PubMed ID: 26547662 [TBL] [Abstract][Full Text] [Related]
20. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]